Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS

Gloved hand holding a vial of mpox vaccine

Earnings

Bavarian Nordic Adopts Optimistic Outlook Amid New Orders for Mpox Vaccine

The Danish biotech on Thursday reported stronger-than-expected earnings and forecasts hitting the upper range of its full-year revenue target amid the ongoing mpox outbreak.

August 23, 2024

1 min read

Tristan Manalac

FDA signage at its headquarters in Maryland

Stomach cancer

FDA Sets Adcomm Meeting to Assess Checkpoint Inhibitors in Stomach Cancer Using PD-L1

The Oncologic Drugs Advisory Committee in a Sept. 26 meeting will discuss whether the regulator should restrict approval of checkpoint inhibitors based on PD-L1 expression levels.

August 23, 2024

2 min read

Tristan Manalac

Novartis head office building in Dorval, Quebec, Canada

Business

Novartis, Versant Launch RNA Kidney Medicines—Focused Borealis

Looking to build on the success of Chinook Therapeutics, founded by Versant in 2019 and acquired by Novartis last year, the companies on Thursday launched Borealis Biosciences with $150 million in funding to develop RNA therapeutics for kidney diseases.

August 22, 2024

2 min read

Kate Goodwin

Downward trendline superimposed on a picture of a man working on financial records

China

WuXi Biologics Takes Net Profit Hit Despite Inking Record Number of New Projects

With the potential passage of the BIOSECURE Act looming, WuXi Biologics reported a 24% drop in net profit in the first half of 2024.

August 22, 2024

2 min read

Tristan Manalac

BioMarin's headquarters in San Francisco

C-suite

BioMarin Brings on Roche, Amgen Alums in Executive Restructuring

As the biotech implements a more focused strategy for its Roctavian hemophilia A gene therapy, BioMarin has recruited two seasoned pharma executives to bolster its C-suite.

August 22, 2024

2 min read

Tristan Manalac

A top-down view of a business team holding a meeting

Startups

BridgeBio Launches GondolaBio With $300M, Transfers Programs to Joint Venture

With the help of third-party investors, the new venture will focus on three genetic and rare diseases: tuberous sclerosis complex, erythropoietic protoporphyria and alpha-A1 antitrypsin deficiency.

August 22, 2024

2 min read

Tristan Manalac

Alzheimer’s disease

Biogen, Eisai’s Leqembi Gets UK Approval but Deemed Too Expensive by NICE

While approved by the Medicines and Healthcare products Regulatory Agency, the Alzheimer’s drug failed to win the backing of the U.K.’s National Institute for Health and Care Excellence, which said that its benefits were “too small to justify the cost.”

August 22, 2024

2 min read

Tristan Manalac

Pictured: FTC sign above a doorway/iStock, Gromit7

Government

Judge Blocks FTC Rule That Banned Most New Noncompete Clauses

The federal judge’s decision Tuesday said the Federal Trade Commission exceeded its statutory authority in implementing a final rule aimed at restricting noncompete clauses.

August 21, 2024

1 min read

Angela Gabriel